Heart pulls sodium meta-analysis over duplicated, and now missing, data

The journal Heart has retracted a 2012 meta-analysis after learning that two of the six studies included in the review contained duplicated data.  Those studies, it so happens, were conducted by one of the co-authors.

The article, “Low sodium versus normal sodium diets in systolic heart failure: systematic review and meta-analysis,” came from an eclectic group of authors from the United States, Canada and Italy (the first author is listed as being at a Wegmans pharmacy in Ithaca, N.Y.). The paper, published online in August 2012, purported to find that:

Heart retracts stent-ReoPro paper over data dispute with authors (save one)

We’re a few months late on this one, but Heart, a BMJ title, issued a fascinating retraction notice in August about a meta-analysis on percutaneous coronary intervention (that’s stenting to you and me) after suffering a heart attack, and the drug abciximab, which is used to prevent clotting and additional near-term heart attacks. Abciximab is sold as ReoPro by Eli Lilly.

The article, “Clinical impact of intracoronary abciximab in patients undergoing primary percutaneous coronary intervention: an individual patient-data pooled analysis of randomised studies,” was published last May. But according to the retraction notice, the authors had neglected to include fresh data, already in the literature before their paper went live, that contradicted their overall findings.

Here’s the notice:

Heart study pulled after production glitch leads to duplicate publication

On reflection, that headline pretty much says it all. But for those readers who took the time to click on the link, here’s the rest of it.

The journal Heart, a title of the BMJ group, has retracted a paper that it published twice: